<DOC>
	<DOCNO>NCT00986817</DOCNO>
	<brief_summary>Ascites common complication cirrhosis . Sodium restriction diuretic first step treatment . Refractory ascites ( respond first step treatment ) treat repeated large volume paracentesis follow intra venous albumin expansion . In pilot study vasoconstrictor agent terlipressin show beneficial effect ascites production . Therefore investigator study effect combine therapy albumin terlipressin recidivation ascites .</brief_summary>
	<brief_title>Terlipressin Cirrhotic Patients With Recidivation Ascites Treated With Paracentesis Albumin</brief_title>
	<detailed_description>About 30 % cirrhotic patient develop ascites . Sodium restriction diuretic first step treatment . Total paracentesis use patient cirrhosis tense ascites . Paracentesis alone find induce decrease effective arterial blood volume . This circulatory dysfunction may induce inhospital complication impair renal function hyponatremia associate significant reduction long term survival . Intravenous albumin administration paracentesis show prevent post paracentesis decrease arterial blood volume . Paracentesis also induce arteriolar vasodilation play major role initiate decrease arterial blood volume . Therefore , administration vasoconstrictor may decrease paracentesis induced arteriolar vasodilation prevent result decrease effective arterial blood volume . Two randomise pilot study suggest Terlipressin may effective intravenous albumin prevent decrease effective arterial blood volume patient cirrhosis treat paracentesis tense ascites . The combined treatment , albumin plus terlipressin , could additional effect may improve ascites patient . In several study combine therapy , albumin plus terlipressin , show beneficial effect cirrhotic patient hepatorenal syndrome characterize sever decrease arterial blood volume vasodilation . In study , combine therapy well tolerated.The aim study compare ascites relapse two group cirrhotic patient recidivation ascites treat paracentesis intravenous albumin perfusion plus terlipressin placebo . In double blind randomize multi-center trial , patient receive albumin perfusion dose 8 g/l remove ascites Terlipressin ( 1mg ) placebo , administrated end paracentesis .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Ascites</mesh_term>
	<mesh_term>Terlipressin</mesh_term>
	<mesh_term>Lypressin</mesh_term>
	<criteria>Patient age 18 year old cirrhosis refractory ascites define international ascites club . Vital status non engage 2 month cardiovascular disease : previous actual angina pectoralis , myocardial infarction , heart failure , rhythm conduction disorder , repolarisation abnormality ECG respiratory disease : previous actual chronic pulmonary insufficiency , asthma uncontrolled hypertension acute portal vein thrombosis ( le 3 month ) currently treat . chronic renal insufficiency ( creatin &gt; 15 mg/L ) severe hepatic encephalopathy Alcoholic hepatitis gastrointestinal bleeding last 3 month hepatocellular carcinoma severe illness life threaten pregnant breastfeeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Refractory ascites</keyword>
	<keyword>Cirrhosis Terlipressin</keyword>
	<keyword>Paracentesis</keyword>
</DOC>